Table 2 Characteristics of the TA patients stratified for therapy with PPIs and for the presence of arterial hypertension
From: Chromogranin-A production and fragmentation in patients with Takayasu arteritis
Therapy with PPIs | Arterial hypertension | |||||
|---|---|---|---|---|---|---|
No (N = 12) | Yes (N = 30) | p value | No (N = 20) | Yes (N = 22) | p value | |
Qualitative variables | ||||||
Sex (F:M) | 11:1 | 28:2 | n.s. | 20:0 | 19:3 | n.s. |
Class of arterial involvement: | ||||||
1 2A 2B 3 4 5 | 1 2 1 0 0 8 | 3 2 2 1 0 22 | n.s. n.s. n.s. n.s. N.A. n.s. | 2 3 1 1 0 13 | 2 1 2 0 0 17 | n.s. n.s. n.s. n.s. N.A. n.s. |
Aneurysms | 6 | 10 | n.s. | 7 | 9 | n.s. |
Steroids | 3 | 27 | <0.001 | 13 | 17 | n.s. |
Immunosuppressive therapy: | 7 | 23 | n.s. | 11 | 19 | 0.04 |
Biologic therapy: TNF blockers Tocilizumab | 4 3 1 | 15 13 1 | n.s. n.s. n.s. | 10 9 1 | 9 7 1 | n.s. n.s. n.s. |
Active disease (NIH criteria) | 0 | 12 | 0.009 | 5 | 6 | n.s. |
Anticoagulants | 3 | 4 | n.s. | 3 | 4 | n.s. |
Arterial hypertension | 4 | 18 | n.s. | N.E. | N.E. | |
Therapy with PPIs | N.E. | N.E. | ||||
Cardiac involvement | 4 | 8 | n.s. | 6 | 6 | n.s. |
Vascular enhancement (N = 30) | 1 | 4 | n.s. | 3 | 2 | n.s. |
Vascular progression (N = 40) | 1 | 8 | n.s. | 5 | 4 | n.s. |
Scalar variables (median and range) | ||||||
Age (years) | 51 (31–66) | 41 (23–62) | 0.060 | 40 (23–66) | 47 (26–65) | n.s. |
Age at TA onset (years) | 36 (21–56) | 28 (17–56) | n.s. | 29 (17–56) | 30 (18–56) | n.s. |
Disease duration (years) | 12 (4–21) | 9 (0–34) | n.s. | 9 (2–21) | 11 (0–34) | n.s. |
Creatinine (mg/dl) | 0.70 (0.44–1.06) | 0.70 (0.56–1.60) | n.s. | 0.67 (0.49–0.89) | 0.75 (0.44–1.61) | 0.084 |
PDN dose (mg/day) | 0 (0–12.5) | 5 (0–35) | <0.001 | 5 (0–25) | 5 (0–35) | n.s. |
N vessels | 4 (1–6) | 4 (1–7) | n.s. | 3 (1–-6) | 4 (1–7) | n.s. |
ESR (mm/h) | 9 (1–23) | 18 (2–78) | 0.059 | 13 (2–73) | 18 (1–78) | n.s. |
Serum CRP (mg/l) | 1.5 (0.1–12) | 3.0 (0.3–40) | 0.104 | 2.0 (0.1-40) | 2.6 (0.3–36.8) | n.s. |
Plasma PTX3 (ng/ml) | 4.1 (1.3–44) | 5.9 (2.2–55) | n.s. | 5.8 (2.5–43.6) | 5.3 (1.3–55.0) | n.s. |
CgAtot (nM) | 1.02 (0.45–2.66) | 3.40 (0.60–7.85) | <0.001 | 1.35 (0.5–3-6.31) | 3.76 (0.45–7.85) | 0.021 |
CgA439 (nM) | 0 (0-0–19) | 0.07 (0–0.78) | n.s. | 0.01 (0–0.44) | 0.07 (0–0.78) | n.s. |
CgA-FRs (nM) | 0.76 (0.22–1.82) | 2.18 (0.28–6.68) | <0.001 | 0.89 (0.39–3.93) | 2.45 (0.22–6.68) | 0.030 |
VS-1 (nM) | 0.10 (0.02–0.34) | 0.25 (0.06–1.15) | 0.001 | 0.11 (0.02–0.79) | 0.32 (0.05–1.15) | 0.024 |
CgA439/CgAtot | 0 % (0–18 %) | 2 % (0–24 %) | n.s. | 0 % (0–18 %) | 2 % (0–24 %) | n.s. |
CgA-FRs/CgAtot | 69 % (50–84 %) | 66 % (47–94 %) | n.s. | 69 % (50–84 %) | 66 % (47–94 %) | n.s. |
VS-1/CgAtot | 12 % (1–24 %) | 10 % (3–27 %) | n.s. | 12 % (1–24 %) | 10 % (3–27 %) | n.s. |
Rank CgA439+ rank VS-1 | 27 (5–50) | 41 (18–83) | 0.002 | 32 (5–64) | 44 (8–83) | 0.023 |